Local Tumor Control, Visual Acuity, and Survival After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007

Dunavoelgyi, Roman; Dieckmann, Karin; Gleiß, Andreas; Sacu, Stefan; Kircher, Karl; Georgopoulos, Michael; Georg, Dietmar; Zehetmayer, Martin; Poetter, Richard

doi:10.1016/j.ijrobp.2010.04.035

Cited by 95 publications

(105 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternative treatments include brachytherapy [14,25,26], gamma-knife radiosurgery [27], proton beam radiation [28,29], fractionated stereotactic radiotherapy [30,31], and partial lamellar sclerouvectomy [32]. However, none of these alternative therapies has been evaluated prospectively.…”

Section: Discussionmentioning

confidence: 99%

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Naseripour¹,

Jaberi²,

Sedaghat³

et al. 2016

jcb

View full text Add to dashboard Cite

Purpose: To evaluate the outcomes of ruthenium-106 ( 106 Ru) brachytherapy in terms of radiation parameters in patients with thick uveal melanomas.Material and methods: Medical records of 51 patients with thick (thickness ≥ 7 mm and < 11 mm) uveal melanoma treated with 106 Ru brachytherapy during a ten-year period were reviewed. Radiation parameters, tumor regression, best corrected visual acuity (BCVA), and treatment-related complications were assessed.Results: Fifty one eyes of 51 consecutive patients including 25 men and 26 women with a mean age of 50.5 ± 15.2 years were enrolled. Patients were followed for 36.1 ± 26.5 months (mean ± SD). Mean radiation dose to tumor apex and to sclera were 71 (± 19.2) Gy and 1269 (± 168.2) Gy. Radiation dose rates to tumor apex and to sclera were 0.37 (± 0.14) Gy/h and 6.44 (± 1.50) Gy/h. Globe preservation was achieved in 82.4%. Preoperative mean tumor thickness of 8.1 (± 0.9) mm decreased to 4.5 (± 1.6) mm, 3.4 (± 1.4) mm, and 3.0 (± 1.46) mm at 12, 24, and 48 months after brachytherapy (p = 0.03). Four eyes that did not show regression after 6 months of brachytherapy were enucleated. Secondary enucleation was performed in 5 eyes because of tumor recurrence or neovascular glaucoma. Tumor recurrence was evident in 6 (11.8%) patients. Mean Log MAR (magnification requirement) visual acuity declined from 0.75 (± 0.63) to 0.94 (± 0.5) (p = 0.04). Best corrected visual acuity of 20/200 or worse was recorded in 37% of the patients at the time of diagnosis and 61.7% of the patients at last exam (p = 0.04). Non-proliferative and proliferative radiation-induced retinopathy was observed in 20 and 7 eyes.Conclusions: Thick uveal melanomas are amenable to 106 Ru brachytherapy with less than recommended apex radiation dose and dose rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Naseripour¹,

Jaberi²,

Sedaghat³

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…With a stereotactic linear accelerator, 60-70 Gy in five fractions was given but this was then reduced to 50 Gy. 41 …”

Section: Radiotherapy For Ocular Tumours C Stannard Et Almentioning

confidence: 99%

Radiotherapy for ocular tumours

Stannard

Sauerwein

Maree

et al. 2012

Eye

104

View full text Add to dashboard Cite

Ocular tumours present a therapeutic challenge because of the sensitive tissues involved and the necessity to destroy the tumour while minimising visual loss. Radiotherapy (RT) is one of several modalites used apart from surgery, laser, cryotherapy, and chemotherapy. Both external beam RT (EBRT) and brachytherapy are used. Tumours of the bulbar conjunctiva, squamous carcinoma and malignant melanoma, can be treated with a radioactive plaque: strontium-90, ruthenium-106

show abstract

“…The SDRT monotherapy tended to be less able to destroy all tumor cells. In other studies 4,[21][22][23] reporting results after fractionated stereotactic radiotherapy, local tumor control between 95.9% and 100% was achieved (Table 2). However, in these series, the tumors being treated were much smaller than were those in our analysis.…”

Section: Commentmentioning

confidence: 83%

“…[1][2][3][4][5][6][7][8][9] Local tumor control rates currently reach more than 90%. 2,[4][5][6]8,9 Small and medium-sized UMs are usually treated with transpupillary thermotherapy or plaque brachytherapy. However, large UMs are still a therapeutic challenge.…”

Section: N the Past Enucleation Was Thementioning

confidence: 99%

“…The most frequent reasons for enucleation were tumor progression and neovascular glaucoma. The fractionated stereotactic radiotherapy studies 4,[21][22][23] reported eye preservation rates between 78.6% and 97.4%. In gamma knife therapy, eye preservation was successful in 78% to 94% of patients 13,[24][25][26][27][28] ; the incidence with PBRT therapy was 54% to 92.3% 12,[29][30][31][32][33] and, with iodine brachytherapy, 76% to 84%.…”

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective Evaluation of Patients With Uveal Melanoma Treated by Stereotactic Radiosurgery With and Without Tumor Resection

Suesskind¹,

Scheiderbauer²,

Buchgeister³

et al. 2013

JAMA Ophthalmol

View full text Add to dashboard Cite

Local Tumor Control, Visual Acuity, and Survival After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007

Cited by 95 publications

References 49 publications

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Radiotherapy for ocular tumours

Retrospective Evaluation of Patients With Uveal Melanoma Treated by Stereotactic Radiosurgery With and Without Tumor Resection

Contact Info

Product

Resources

About